'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study - Reuters

Endpoints News

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study Reuters (Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study ... Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 ...Business Wire (press release) all 4 news articles »

from Health - Google News http://ift.tt/2C35JgX